Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa
Phase II Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-unexposed, BCG Naive Newborn Infants in South Africa
Sponsor: Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa
This PHASE2 trial investigates Tuberculosis and is currently completed. Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Aug 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Children's Infectious Diseases Clinical Research Unit (KID-CRU), South Africa
- HJ-CTC George, South Africa
- Serum Life Science Europe GmbH
- Triclinium Johannesburg, South Africa
- University of Stellenbosch
For direct contact, visit the study record on ClinicalTrials.gov .